SCHEMBL18227002

SCHEMBL18227002

CN1C(=O)COc2cc(Cl)ncc21

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.48
CYP11B1 P15538 1/20 0.48
GABRA5 P31644 5/20 0.45
GABRG2 P18507 4/20 0.45
GABRB3 P28472 4/20 0.45
PDE3B Q13370 3/20 0.41
PDE3A Q14432 3/20 0.41
GABRA1 P14867 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
IDH1 O75874 1/20 0.37
GRM4 Q14833 1/20 0.37
KMO O15229 1/20 0.35
HTR1A P08908 1/20 0.34
HTR2C P28335 1/20 0.34
TERT O14746 1/20 0.34
SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20527122 0.81 CYP11B2 (0.48) CYP11B2CYP11B1GABRA5GABRG2GABRB3
Hydrochloric Acid SCHEMBL18226990 0.80 CYP11B2 (0.47) CYP11B2CYP11B1GABRA5GABRG2GABRB3
SCHEMBL22969002 0.76 MAPT (0.33) GABRA5GABRG2GABRB3
SCHEMBL2228272 0.75 CYP11B2 (0.47) CYP11B2CYP11B1GABRA5GABRG2GABRB3
SCHEMBL30954127 0.72 CYP11B2 (0.42) CYP11B2CYP11B1GABRA5GABRG2GABRB3
SCHEMBL13178859 0.72 GABRG2 (0.43) CYP11B2CYP11B1GABRA5GABRG2GABRB3
SCHEMBL16972829 0.72 CYP11B2 (0.42) CYP11B2CYP11B1GABRA5GABRG2GABRB3
SCHEMBL31125023 0.71 CYP11B2 (0.46) CYP11B2CYP11B1PDE3BPDE3A
SCHEMBL31125026 0.71 CYP11B2 (0.46) CYP11B2CYP11B1PDE3BPDE3A
SCHEMBL13780087 0.71 KMO (0.58) PDE3BPDE3AIDH1KMOTERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180289718-A1 FUSED IMIDAZOLE COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2018-10-11 US disclosed
US-10016439-B2 Fused imidazole compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2018-07-10 US disclosed
US-20160331757-A1 FUSED IMIDAZOLE COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180289718-A1 FUSED IMIDAZOLE COMPOUNDS GABRA5, CHRNA5, GABRP CYP11B2 209/4885CYP11B1 150/4885GABRA5 1/4885
US-20160331757-A1 FUSED IMIDAZOLE COMPOUNDS GABRA5, CHRNA5, GABRP CYP11B2 209/4885CYP11B1 150/4885GABRA5 1/4885
US-10016439-B2 Fused imidazole compounds GABRA5, CHRNA5, GABRP CYP11B2 209/4885CYP11B1 150/4885GABRA5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.